Vistagen drug trial fails to meet efficacy targets
Statements (2)
- Bearish
Vistagen's anxiety disorder drug failed to meet its primary objective in the late-stage clinical trial
- Bearish
Vistagen's shares are likely to fall significantly after its late-stage trial results failed to meet primary efficacy targets.